Administration of an anti-IL22 blocking antibody results in higher bacterial loads in the lungs and dissemination of bacteria to spleen (Aujla et al.2008), whereas therapeutic administration of IL22 attenuates Klebsiella-triggered peritonitis (Zheng et al.2016). The gene discussed is IL22; the disease is peritonitis.